SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing Palantirs opportunities in sovereign AI and customized software, has helped fuel a rally to new highs. Bulls celebrate the momentum and potential AI growth, while bears argue the valuation is stretched and warn of a pullback.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares sold off sharply after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, raising concerns about a future rival to established wireless carriers. Traders debate whether the threat could pressure T-Mobiles pricing and market share or whether the selloff overstates a challenge that would require substantial infrastructure and time to develop.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has pressured AT&T shares as traders weigh the prospect of a new wireless competitor. The community is divided between those who see a lasting threat and dip buyers who argue that building a competitive network will take years and that the selloff is excessive.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs agreement to acquire low-band spectrum has raised concerns that Starlink Mobile could eventually challenge established wireless carriers, weighing on Verizon shares. Traders are split between viewing the selloff as an overreaction given the time and infrastructure needed to build a competing network and treating the move as a longer-term competitive threat; some see the decline as a dividend-driven buying opportunity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Nasdaq-100 reentry and anticipated index-fund buying are drawing attention alongside optimism about a planned NIH effort to accelerate personalized cancer vaccines and the companys Merck-partnered melanoma-vaccine program. Bulls point to momentum and possible short-covering, while skeptics argue the rally has outrun fundamentals and the cancer-vaccine opportunity remains uncertain.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Attention centers on Himaxs upcoming quarterly results and whether revenue growth and margins can support its valuation, alongside longer-term hopes for CPO and automotive demand. Traders are split between buying the pullback and concerns about semiconductor weakness and rumored CPO competition.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Curaleafs unsolicited Aurora Cannabis takeover bid is dominating discussion, with traders weighing the enhanced offer against Aurora shareholders resistance and debating whether the deal will proceed or draw competing interest. Views are split between those who see the acquisition as a strategic expansion and those who consider the terms inadequate for Aurora holders.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgos autonomous-lab expansionincluding Araceli imaging integration and Boston lab access for NSF X-Labs researchersis fueling attention, with bulls viewing it as progress toward AI-driven biology infrastructure. Skeptics counter that partnerships and lab buildouts still need to translate into revenue and stronger financial execution.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is drawing attention around managements updates on optical-engine production, customer qualification, manufacturing yields and planned capacity expansion. Bulls view the reported progress as evidence the company is moving toward commercialization, while skeptics remain frustrated by limited customer and order details and question whether the ramp will translate into meaningful revenue.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on Trumps reported agreement for Russia to supply diesel amid elevated fuel costs and oil-market disruption linked to the Iran conflict. Many traders criticize the move as financing Moscow and undermining Ukraine, while some defend it as a practical effort to ease prices; the deals scale and likely effect remain debated.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marksans Pharma Gets USFDA Nod for Generic Tessalon Capsules

… infections. The approval strengthens Marksans Pharma ’s portfolio in the U.S … in the respiratory segment. Marksans Pharma Limited, headquartered in Mumbai, … manufacturing, and marketing of generic pharmaceutical formulations across global markets. The …

Marksans Pharma arm gets marketing nod for Cetirizine Dihydrochloride 1 mg/ml Oral Solution in UK

Mumbai: Marksans Pharma Limited has announced that its … mg Film-coated Tablets). Marksans Pharma Limited, headquartered at Mumbai, India … , manufacturing & marketing of generic pharmaceutical formulation in the global markets …

Brief Healthcare: IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening and more

In this briefing: IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential GENOVA (9341 JP): 1H FY03/26 flash update 1. IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening Izotropic is a medical device company that has developed an innovative machine that will allow for women to have more accurate and comfortable screenings for breast cancer. For years, women with dense breasts have had cancers missed or have had to undergo additional, expensive tests. With the Izotropic machine, costs for insurance companies will go down, accuracy will be greatly increased, and comfort will improve. 2. Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm.

Brief Healthcare: Fortis Healthcare Ltd - Strong Quarter with Margin Expansion and more

In this briefing: Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential GENOVA (9341 JP): 1H FY03/26 flash update Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs 1. Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm. Stable ARPOB and Occupancy: ARPOB stood at Rs 68,800, marking a 5.9% YoY increase, while occupancy rose to 71% (up 100 bps QoQ), supported by a 13% YoY growth in occupied bed days. EBITDA margin expanded to 23.9%, up 200 bps YoY and 120 bps QoQ. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: RITES Ltd - Strong Orderbook to Drive Growth and more

In this briefing: RITES Ltd - Strong Orderbook to Drive Growth Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth Telecom Industry Snapshot- September 2025: Jio and Airtel Drive Data-Led Growth UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. RITES Ltd - Strong Orderbook to Drive Growth Strong Order Book: In Q2FY26, the company secured over 150 new orders worth Rs 851 Cr, taking the total order book to Rs 9,090 Cr and ensuring strong revenue visibility for the next 2–2.5 years. Notably, 34% of the order book comprises the high-margin consultancy segment, underscoring its profitability profile. Backed by a robust pipeline and increasing opportunities across the infrastructure space, the company remains well-positioned to deliver sustainable long-term growth. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs and more

In this briefing: BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs GAS [BUY +25.0%] - Strong Volume Recovery to Boost 2026 Core NPAT KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs We upgrade our rating for BMP to BUY from OUTPERFORM and raise our target price (TP) by 24% to VND192,500/share. The share price has risen 14% over the past two months. Our higher TP is due to (1) rolling our TP forward to end-2026 and (2) raising our 2026-30F NPAT-MI forecasts by ~20% each year. The higher earnings forecast is mainly driven by our higher GPM forecasts of ~3.5 percentage points each year during this period, respectively. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth and more

In this briefing: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Primer: Hyundai Engineering (064540 KS) - Nov 2025 1. KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth We reiterate our BUY rating for KDH and raise our target price (TP) by 3% to VND48,500/share. Our higher TP is mainly driven by a higher valuation for Binh Trung Dong, increased book value for undisclosed pipeline, and rolling our TP horizon forward to end-2026. We forecast 2025F NPAT-MI of VND1.04tn (USD39.5mn; +29% YoY; +1% vs prior), with Q4 2025F NPAT-MI of VND484bn (USD18mn; 2x QoQ and +22% YoY), driven by continued handovers of presold low-rise units at ‘Gladia by the Waters’ (11.8 ha; JV with Keppel; KDH 51%). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Equities Bottom-Up: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth and more

In this briefing: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. Coupang: Facing Increasing Risk of a Potential Ban on Early Dawn Deliveries - Number One Risk Factor Topline Flash Note: Bank of Punjab (BOP): Corporate Briefing Key Takeaways The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth We reiterate our BUY rating for KDH and raise our target price (TP) by 3% to VND48,500/share. Our higher TP is mainly driven by a higher valuation for Binh Trung Dong, increased book value for undisclosed pipeline, and rolling our TP horizon forward to end-2026. We forecast 2025F NPAT-MI of VND1.04tn (USD39.5mn; +29% YoY; +1% vs prior), with Q4 2025F NPAT-MI of VND484bn (USD18mn; 2x QoQ and +22% YoY), driven by continued handovers of presold low-rise units at ‘Gladia by the Waters’ (11.8 ha; JV with Keppel; KDH 51%).

Brief India: UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape and more

In this briefing: UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Capillary Technologies India IPO- Forensic Analysis Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Shadowfax Technologies Pre-IPO Tearsheet 1. UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape RBI and NPCI are rolling out the Credit Line on UPI (CLOU) , allowing instant digital credit within UPI apps- effectively merging payments and lending. CLOU leverages India’s most trusted digital infrastructure to expand formal credit access , especially for new-to-credit consumers , and could be the foundation for a data-driven lending model. By combining UPI Credit Lines with a forthcoming Digital Payment Score (DPS) , India may transition from a payments-led to a credit-led digital economy - redefining financial inclusion and retail lending economics. 2. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a ' Zero 483 Observation' clearance from the USFDA , completely de-risking its largest-ever capex.

Brief Growth Ideas: Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. and more

In this briefing: Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Primer: Hyundai Engineering (064540 KS) - Nov 2025 Primer: Zedcor (ZDC CN) - Nov 2025 1. Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. 4Q25 seasonal outlook? Silergy expects flat to slightly up QoQ, similar to past years. Silergy does see consolidation, and given its stronger financials, product breadth, and R&D capabilities, the company remains a top supplier and will continue to gain share. Will 1H next year be better than 2H this year?Hard to say because of Chinese New Year seasonality.We expect YoY growth, but not strong yet. 2. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a ' Zero 483 Observation' clearance from the USFDA , completely de-risking its largest-ever capex.

Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. Its product portfolio includes tablets, hard capsules, soft gelatin capsules, oral liquids, and ointments. It operates through the following geographical segments: US and North America, Europe and UK, Australia and New Zealand, India, and Rest of World. The company was founded by Mark Bosco Saldanha on April 16, 1992 and is headquartered in Mumbai, India.

Current Price	308.70
Prev Close	308.00
Open	308.50
Dividend Yield	0.57%
50-Day Moving Average	316.51
Beta	0.12
Avg. Volume	2.56M
PE Ratio	27.11

52-Week High	350.95
52-Week Low	155.00
Market Capitalization	139.53B
EPS (Annual)	9.22
Price to Book	4.63
Revenue Per Employee	17.48M

Feed

News

Sentiment

Fundamentals

Info

MARKSANS.NSE Fundamentals